Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases.
Objective: to perform a cost-effectiveness analysis of asthma treatment with budesonide/formoterol against other treatment options used at Mexico’s National Institute for Respiratory Diseases. Methods: A complete economic evaluation of cost-effectiveness from a public health perspective, comparin...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Colegio Mexicano de Inmunología Clínica y Alergia, A.C.
2024-12-01
|
| Series: | Revista Alergia México |
| Subjects: | |
| Online Access: | https://revistaalergia.mx/ojs/index.php/ram/article/view/1295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846102200539938816 |
|---|---|
| author | María del Carmen Cano-Salas José L. Miguel-Reyes Erika C. López-Estrada Jorge Salas-Hernández Monserrat E. Arroyo-Rojas Mauricio Castañeda-Valdivia Monserrat Escobar-Preciado Homero Garcés-Flores Silvia Guzmán- Vázquez Sergio R. García-García Herman Soto-Molina |
| author_facet | María del Carmen Cano-Salas José L. Miguel-Reyes Erika C. López-Estrada Jorge Salas-Hernández Monserrat E. Arroyo-Rojas Mauricio Castañeda-Valdivia Monserrat Escobar-Preciado Homero Garcés-Flores Silvia Guzmán- Vázquez Sergio R. García-García Herman Soto-Molina |
| author_sort | María del Carmen Cano-Salas |
| collection | DOAJ |
| description |
Objective: to perform a cost-effectiveness analysis of asthma treatment with budesonide/formoterol against other treatment options used at Mexico’s National Institute for Respiratory Diseases.
Methods: A complete economic evaluation of cost-effectiveness from a public health perspective, comparing the use of budesonide/formoterol as maintenance therapy with fluticasone/vilanterol in 103 female asthma patients managed at INER between 2015 and 2021.
Results: Average cost per patient was $743.23 USD, $733.36 USD for budesonide/formoterol and $767.24 USD for fluticasone/vilanterol. Pharmacological treatment represented over 70% of management costs for both groups, followed by follow-up visits and exacerbation management costs. LABA-ICS represented the highest proportion of pharmacologic management costs with a statistically significant difference amongst groups with an incremental cost of $80.17 USD for the fluticasone/vilanterol group. The budesonide/formoterol group showed an ICER of $613.31 USD for reducing the proportion of patients experiencing exacerbations during follow-up. Considering the willingness to pay threshold based on one GDP per capita ($10,902.98 USD in 2022), budesonide/formoterol represented a very cost-effective option.
Conclusions: The ICER favored budesonide/formoterol over fluticasone/vilanterol in terms of cost-effectiveness. A 5.5% reduction in patient exacerbations indicated decreased disease burden. While not statistically significant, fewer exacerbations per patient might still cut costs by lowering emergency visits and hospitalizations.
Keywords: Cost-effectiveness analysis; Asthma; Budesonide; Formoterol fumarate.
|
| format | Article |
| id | doaj-art-586a9d3a0b114dacafc044b7ca02daf8 |
| institution | Kabale University |
| issn | 0002-5151 2448-9190 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Colegio Mexicano de Inmunología Clínica y Alergia, A.C. |
| record_format | Article |
| series | Revista Alergia México |
| spelling | doaj-art-586a9d3a0b114dacafc044b7ca02daf82024-12-27T19:33:59ZengColegio Mexicano de Inmunología Clínica y Alergia, A.C.Revista Alergia México0002-51512448-91902024-12-0171410.29262/ram.v71i4.1295Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases.María del Carmen Cano-SalasJosé L. Miguel-ReyesErika C. López-EstradaJorge Salas-HernándezMonserrat E. Arroyo-RojasMauricio Castañeda-ValdiviaMonserrat Escobar-PreciadoHomero Garcés-FloresSilvia Guzmán- VázquezSergio R. García-GarcíaHerman Soto-Molina Objective: to perform a cost-effectiveness analysis of asthma treatment with budesonide/formoterol against other treatment options used at Mexico’s National Institute for Respiratory Diseases. Methods: A complete economic evaluation of cost-effectiveness from a public health perspective, comparing the use of budesonide/formoterol as maintenance therapy with fluticasone/vilanterol in 103 female asthma patients managed at INER between 2015 and 2021. Results: Average cost per patient was $743.23 USD, $733.36 USD for budesonide/formoterol and $767.24 USD for fluticasone/vilanterol. Pharmacological treatment represented over 70% of management costs for both groups, followed by follow-up visits and exacerbation management costs. LABA-ICS represented the highest proportion of pharmacologic management costs with a statistically significant difference amongst groups with an incremental cost of $80.17 USD for the fluticasone/vilanterol group. The budesonide/formoterol group showed an ICER of $613.31 USD for reducing the proportion of patients experiencing exacerbations during follow-up. Considering the willingness to pay threshold based on one GDP per capita ($10,902.98 USD in 2022), budesonide/formoterol represented a very cost-effective option. Conclusions: The ICER favored budesonide/formoterol over fluticasone/vilanterol in terms of cost-effectiveness. A 5.5% reduction in patient exacerbations indicated decreased disease burden. While not statistically significant, fewer exacerbations per patient might still cut costs by lowering emergency visits and hospitalizations. Keywords: Cost-effectiveness analysis; Asthma; Budesonide; Formoterol fumarate. https://revistaalergia.mx/ojs/index.php/ram/article/view/1295Cost-effectiveness analysisasthmabudesonideformoterol fumarate |
| spellingShingle | María del Carmen Cano-Salas José L. Miguel-Reyes Erika C. López-Estrada Jorge Salas-Hernández Monserrat E. Arroyo-Rojas Mauricio Castañeda-Valdivia Monserrat Escobar-Preciado Homero Garcés-Flores Silvia Guzmán- Vázquez Sergio R. García-García Herman Soto-Molina Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases. Revista Alergia México Cost-effectiveness analysis asthma budesonide formoterol fumarate |
| title | Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases. |
| title_full | Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases. |
| title_fullStr | Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases. |
| title_full_unstemmed | Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases. |
| title_short | Cost-effectiveness of budesonide-formoterol in maintenance therapy of asthma patients at Mexico’s National Center for Respiratory Diseases. |
| title_sort | cost effectiveness of budesonide formoterol in maintenance therapy of asthma patients at mexico s national center for respiratory diseases |
| topic | Cost-effectiveness analysis asthma budesonide formoterol fumarate |
| url | https://revistaalergia.mx/ojs/index.php/ram/article/view/1295 |
| work_keys_str_mv | AT mariadelcarmencanosalas costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT joselmiguelreyes costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT erikaclopezestrada costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT jorgesalashernandez costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT monserratearroyorojas costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT mauriciocastanedavaldivia costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT monserratescobarpreciado costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT homerogarcesflores costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT silviaguzmanvazquez costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT sergiorgarciagarcia costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases AT hermansotomolina costeffectivenessofbudesonideformoterolinmaintenancetherapyofasthmapatientsatmexicosnationalcenterforrespiratorydiseases |